Morphic Therapeutic Appoints Nisha Nanda to Board of Directors

Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced the appointment of Nisha Nanda, Ph.D., to its Board of Directors. Dr. Nanda currently serves as the chief development officer for Loxo Oncology at Lilly.

"Nisha's expertise overseeing preclinical and clinical-stage development strategy will be an asset to Morphic as we advance the leading oral integrin portfolio in the industry," said Gustav Christensen, chairman of the Board of Directors of Morphic Therapeutic. "We look forward to Nisha's drug development guidance and contributions across multiple therapeutic areas. On behalf of Morphic, I welcome Nisha to the team."

Dr. Nanda has two decades of experience in the biopharma industry, holding various roles of responsibility in both clinical and preclinical development. Prior to Loxo Oncology, Dr. Nanda worked on the clinical development of carfilzomib (Kyprolis) and the approval of omacetaxine (Synribo). Her career in drug development has included roles at Onyx, ChemGenex, Portola, Millennium and COR. Dr. Nanda holds a Ph.D. in biochemistry and molecular genetics from the University of New South Wales and the Victor Chang Cardiac Research Institute in Sydney, Australia.

"This is an auspicious time to join the Morphic team as they move into mid-stage clinical studies of MORF-057 in IBD and build the clinical strategy for their other oral integrin programs based on insights from the MInT Platform for integrin discovery," commented Dr. Nanda. "I'm excited by Morphic's mission to deliver the known power of integrin inhibition with the convenience and control that oral therapies provide and look forward to providing strategic input as the pipeline matures."

About Morphic Therapeutic

Morphic Therapeutic is a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, including autoimmune, cardiovascular, and metabolic diseases, fibrosis and cancer. In collaboration with AbbVie, Janssen, and Schrödinger, Morphic is advancing its pipeline and discovery activities using its proprietary MInT technology platform which leverages the Company's unique understanding of integrin structure and biology.